GFP Adeno-Associated Virus ( AAV-r3.45 )

Adeno-associated virus (AAV) is a parvovirus whose 4.7kb single-stranded DNA genome contains two genes (rep and cap), and AAV-based vectors have been shown to be safe and effective for clinical applications. Exposure to AAV results in persistent latent infection in a large number of dividing and non-dividing cells. In addition, the AAV vector genome can mediate homologous recombination with target sequences in the cellular genome with an efficiency 1-fold higher than that of plasmid constructs. This feature has been successfully applied to cells that AAV can efficiently transduce, including fibroblasts and more recently mesenchymal stem cells, which has led to the development of new animal models of human diseases. Although AAV-mediated gene expression and targeting are effective tools for stem cell research, unfortunately, AAV vectors have extremely low efficiency for gene delivery in multiple stem cell types. GFP adeno-associated virus (AAV-r3.45) is an advanced biotechnology tool characterized by capsid engineering and modification. The modification involves the strategic insertion of the peptide sequence TQVGQKT at position I587 of the viral capsid. The engineered capsid of AAV-r3.45 is optimized to target neural stem cells, a key cell type in a variety of research and therapeutic applications. Insertion of a peptide at I587 significantly increases the affinity and specificity of the virus for these cells, ensuring efficient delivery and expression of the GFP gene.